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Protoporphyna is a genetic disorder in which liver damage is caused by
the toxic effect ofprotoporphyrin accumulation in the liver. In this study
protoporphyrin was measured in the resected livers of 7 patients who
had livertransplantation and an additional patient from whom liver tis-
sue was obtained post mortem. Comparison of liver, erythrocyte and
serum protoporphyrin levels demonstrated a marked gradient between
these compartments: erythrocyte, 5781 ± 655 pg/dl; serum, 384 ± 102
pg/dl; liver 377,238 ± 55,568 pg/100 gm wet weight, (mean ± SE).
Protoporphyrin levels in bile of 3 patients were 55, 559, and 1,153
g/dl, indicating a gradient between liver and bile as well. Examination
of the livers by polarization microscopy and electron microscopy
demonstrated protoporphyrin pigment crystals. In one patient who had
recurrent liver disease after transplantation, the protoporphyrin concen-
tration in the graft at the time ofdeath was similar to that in the resect-
ed liver. These data indicate that liver protoporphyrin levels in patients
with advanced protoporphyric liver disease are much higher than levels
in blood and bile, in part because protoporphyrin forms crystalline
deposits in liver tissue. Thus, progressive hepatic accumulation of pro-
toporphyrin occurs in the face of impaired biliary excretion. An intrin-
sic defect in hepatic excretion ofprotoporphyrin is probably not neces-
sary for this condition to develop because liver disease can occur in the
graft following transplantation.
INTRODUCTION
Protoporphyria is a genetic disorder of porphyrin metabolism which was first
described in 1961 [1]. The enzyme defect which underlies protoporphyria is in ferro-
chelatase [2, 3], which catalyzes the insertion of iron into protoporphyrin to form heme.
As a consequence of decreased ferrochelatase activity, there is excessive accumulation
and excretion ofprotoporphyrin.
The major clinical feature is photosensitivity [1]. This is due to the photoactive prop-
erties ofprotoporphyrin on skin tissue [4, 5]. Liver disease, which is a less common but
more important clinical feature [6-9], is due to the toxic effect ofprotoporphyrin on liver
structure andfunction [10-12]. Protoporphyrin is excreted only in bile, and the liveris thus
confronted with the excess protoporphyrin that is produced. irrespective of the tissue
source. Histological examination of liver tissue from patients with advanced protopor-
phyric liverdisease reveals extensive deposits ofdark brown pigment which are composed
of protoporphyrin [8, 13]. However, there is only limited information regarding the
numerical quantity ofprotoporphyrin in liver tissue.
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In this report, information is provided regarding the concentration ofprotoporphyrin
in the livers of 8 patients with advanced protoporphyric liver disease, comparing this to
the concentrations in blood and bile. In 4 patients who had liver transplantation, proto-
porphyrin levels were also measured in the graft at various times aftertransplantation. The
study was approved by the Institutional Review Boards at theUniversity ofMinnesota and
The University ofAlabama at Birmingham.
MATERIALS AND METHODS
The patient population consisted of3 males and 5 females with an age range of 13 to
51 years (Table 1). Seven patients (patients 1-7) had liver transplantation because ofliver
failure due to protoporphyric liver disease. Blood samples were obtained from patients
just prior to transplantation, and bile was aspirated from the gallbladder of 2 patients at
the time of transplantation. A portion of the resected liver specimen was obtained from
each patient. In patient 8, liver tissue was obtained at postmortem exam following the
patient's death from liver failure. A bile sample was collected from this patient premortem
through a cholecystostomy tube.
Erythrocyte and serum protoporphyrin levels were measured fluorometrically after
solvent partitioning [12, 14]. The liver porphyrin concentrations were determined fluoro-
metrically afterextracting aportion oftissue with 0.6 N perchloric acid/methanol (1:1 v/v)
[12, 14]. The porphyrin concentrations in bile samples were also measured fluorometri-
cally, and high performance liquid chromatography was done on bile to determine the por-
phyrin profile [12, 15].
The liver specimens were all examined by polarization microscopy as previously
described [16], and some were also examined by electron microscopy [8, 16].
Table 1. Protoporphyrin levels (PP) in patients with advanced protoporphyric liver disease.
Patient Age/Sex Erythrocyte PP Serum PP Liver PP Serum Bilirubin
(pg/dl) (pg/dl) (pg/lOOg wet wt) mg/dl
1 S1/M 5276 160 395,700 10.8
2 38/F 5131 144 589,400 12.7
3 15/M 6470 236 459,900 4.7
4 18/F 6488 836 260,600 13.8
5 13/M 7679 448 522,600 8.5
6 14/F 2450 95 440,200 3.1
7 36/F 8240 362 170,800 15.0
8 33/F 4516 790 178,700 18.1
Mean 27 ±5 5781 655 384± 102 377,238 ± 55,568 10.8 ± 1.8
± SE
Normal/control 20-65 0 20-100 0 - 1.5
324Bloomer: Protoporphyrin metabolism inprotoporphyric liver disease
RESULTS
The erythrocyte and serum levels of protoporphyrin in the patients (Table 1) were
increased compared to patients with protoporphyria who do not have liver disease, in
whom the levels usually are less than 2,000 pg/dl and 50 pg/dl respectively. This differ-
ence is due principally to the retention ofprotoporphyrin in blood because ofthe impaired
liver function. Following liver transplantation, the erythrocyte and serum protoporphyrin
levels declined to 1,765 ± 365 mg/dl and 31 ± 27 mg/dl, respectively, concomitant with a
decrease in the serum bilirubin level to 0.9 ± 0.3 mg/dl and reflecting the improved hepat-
ic function.
The liver ofeach patient was enlarged, firm in consistency and black in color. Diffuse
red fluorescence was demonstrated by fluorescence microscopy in most of the hepato-
cytes. Histological examination demonstrated afinely nodularcirrhosis with active hepat-
ocellular necrosis, portal inflammation and cholestasis. There were extensive deposits of
brown pigment in hepatocytes, Kupffer cells and biliary structures. Pigment deposits in
hepatocytes were usually in the form of small homogenous droplets or coarse granules.
Several of the pigment deposits were birefringent when examined by polarization
microscopy, and electron microscopy demonstrated amorphous material in which were
imbedded numerous electron-dense crystals. The crystalline deposits lay free in the cyto-
plasm ofthe hepatocytes, but in Kupffer cells were exclusively in lysosomes.
The protoporphyrin levels in the livers were greatly in excess of the levels in ery-
throcytes and serum (Table 1). It could not be determined by the method used to extract
and measure protoporphyrin in liver as to how much was in crystalline form and how
much was soluble. Bileprotoporphyrin levels in 3 patients wereelevated compared to con-
trol subjects without protoporphyria, but were less than those in patients with protopor-
phyria who do not have liver disease (Table 2) [15]. This suggests that biliary excretion of
protoporphyrin was impaired in the patients, as would be expected because of the struc-
tural liver damage which had occurred.
Table 2. Bile porphyrin levels in patients with protoporphyria.
Total Bile Porphyrin Distribution ofPorphyrins (percent)
(Iggdl) Protoporphyrin Coproporphyrin Other
Patient 2 1240 93 7 0
7 621 90 10 0
8 58 95 5 0
Patients without 2874±1185t 84 ± 7 7 2 9 4
liver disease (n=6)*
Control(n= 17)* 46±9 12±2 79±3 8±2
t Mean ± SE
*These data were included in a previous publication [15].
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Table 3. Protoporphyrin concentrations gradients.
Patient Erythrocyte/Serum* Liver/Serum* Liver/Bile*
1 33 2473 -
2 36 4093 511
3 27 1949 -
4 8 312 -
5 17 1167 -
6 26 4634 -
7 21 467 306
8 6 226 3249
mean 22 ±4 1915 ± 605 1355 949
± SE
*Concentration ratios: Erythrocyte/serum = (pg/dlcells)/(pg/dl serum); liver/serum = (pg/100 g wet
wt liver)/(pg/dl serum); liver/bile = (pg/100 g wet wt liver)/(pg/dl bile).
As a consequence of the marked hepatic levels ofprotoporphyrin, a significant con-
centration gradient existed between liver and blood and between liver and bile (Table 3).
Thus the liver was the most significant repository ofprotoporphyrin accumulation.
In 4 patients, protoporphyrin levels were measured in the graft at varying periods fol-
lowing livertransplantation (Table4). Ineachcase the level was increased when compared
to nonporphyric control specimens. In one patient there was a progressive increase in the
protoporphyrin level, and this patient developed a recurrence ofprotoporphyric liver dis-
ease which led to his death 5 years after transplantation (patient 5). Post mortem exami-
nation revealed a black, cirrhotic liver with extensive protoporphyrin pigment deposits.
The protoporphyrin level was 507,800 mg/100 g wet weight, compared to a level of
522,600 in his resected liver. A detailed report of this patient's post-transplant course has
been previously published [17].
Table 4. Protoporphyrin levels (PP) in the graft after liver transplantation.
Patient Time afterTransplantation Graft PP (pg/100 g wet wt)
2 13 mos 1180
3 yrs 2700
5 yrs 350
3 13 mos 44,900
4 11 mos 11,700
5 8 mos 620
3 yrs 134,000
5 yrs 507,800
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Figure 1. Development of liver damage in protoporphyria. As a consequence of deficient fer-
rochelatase activity in heme-forming tissues, there is excess protoporphyrin that must be excreted in
bile. When liver injury develops as a result of protoporphyrin toxicity, biliary excretion does not
keep pace with the excess protoporphyrin that is formed. This causes progressive protoporphyrin
accumulation in liver tissue and accelerated injury. Protoporphyria crystals form in liver tissue when
a high concentration is reached
DISCUSSION
Hepatic ferrochelatase activity is deficient in patients withprotoporphyria [3], and the
liver may therefore contribute to the excess production of protoporphyrin. Several differ-
ent types of studies have provided evidence for this possibility [18-22]. However, the
extent of the liver's contribution is uncertain, and the bone marrow is probably the major
source of the excess protoporphyrin in most patients. Nevertheless, the significant
decrease in hepatic ferrochelatase activity that has been observed in patients with
327Bloomer: Protoporphyrin metabolism in protoporphyric liver disease
advanced liver disease (to a level that is 4 to 20 percent of that in normal or control liver
tissue) suggests that the liver may make an important contribution in this situation [23].
The more critical role of the liver in protoporphyria is to excrete the excess protopor-
phyrin that is formed, irrespective of the tissue source. The excretory pathways of the por-
phyrin compounds are determined primarily by their aqueous solubility, and hence by
their number of carboxyl groups. Protoporphyrin, which has only 2 carboxyl groups, is
poorly aqueous soluble and is excreted virtually entirely in bile. Experimental studies have
documented that protoporphyrin is toxic to liver function, impairing bile formation and
the activity of membrane-bound enzymes [10, 11]. As patients develop liver injury from
protoporphyrin toxicity, the liver becomes less able to excrete the excess protoporphyrin
that is formed (Figure 1). This leads to progressive protoporphyrin accumulation in liver
tissue and accelerated injury. The basis of the formation of protoporphyrin crystals is
uncertain. The high concentration that protoporphyrin reaches in the liver is undoubtedly
one factor. Preliminary studies suggest that complexation of protoporphyrin to calcium
may be another factor [24].
Studies with the isolated perfused rat liver indicate that hepatic uptake of protopor-
phyrin occurs by simple or facilitated diffusion, continuing at a significant rate even when
the excretion into bile becomes impaired [25]. The intracellular transport of proto-
porphyrin is probably by nonvesicular carriers, which are targeted to the canalicular mem-
brane, since intracellular transport is not inhibited by colchicine or monensin [26].
Cytosolic proteins such as the fatty acid binding protein and/or phospholipid transfer pro-
teins may affect the intracellular binding and transport [27, 28]. Secretion of protopor-
phyrin into bile appears to be linked to phospholipid secretion [26]. The mdr2 P-glyco-
protein is essential for biliary phospholipid excretion [29], and mice that are homozygous
for disruption ofthe mdr2 P-glycoprotein also have a marked impairment of biliary secre-
tion of protoporphyrin [30].
Bile acids facilitate the excretion of protoporphyrin into bile by increasing the con-
centration ofprotoporphyrin that can be attained. This is related to the number of hydrox-
yl groups and their location in the bile acid [26, 31]. Cholate increases the biliary excre-
tion of protoporphyrin more than chenodeoxycholate, which in turn has a greater affect
than ursodeoxycholate. Biliary protoporphyrin thrombi also form at a lower concentration
of protoporphyrin in bile during infusion with ursodeoxycholate than with the other two
bile acids [31]. Thus, the administration of ursodeoxycholate to patients with protopor-
phyric liver disease must be done cautiously. Chenodeoxycholate has been administered
to patients, with the unexpected result that fecal, bile and blood levels of protoporphyrin
decreased, suggesting that protoporphyria synthesis was reduced [32].
Since protoporphyric liver damage may occur in the graft following liver transplan-
tation, it is unlikely that an intrinsic defect in hepatic protoporphyrin excretion is a neces-
sary factor in the development ofthis condition. Every patient who is transplanted for pro-
toporphyric liver disease thus has the risk of recurrent disease in the graft. Further defin-
ition of the mechanism by which the liver excretes protoporphyrin into bile is desirable.
Measures to facilitate biliary excretion could be instituted in patients with early liver dam-
age and would hopefully reverse that condition, and could be routinely used in patients
who have had liver transplantation to prevent damage to the graft.
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